SCHEMBL411712

SCHEMBL411712

CC(C)(C(N)=O)C(C)(C)C(C(=O)O)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
POLB P06746 5/20 0.44
ALDH1A1 P00352 4/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 1/20 0.43
TP53 P04637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
HPGD P15428 1/20 0.42
ALOX12 P18054 1/20 0.42
NFKB1 P19838 1/20 0.42
APEX1 P27695 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
DNMT1 P26358 3/20 0.41
TDP1 Q9NUW8 1/20 0.39
TNF P01375 2/20 0.39
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL411858 0.88 LMNA (0.46) LMNAPOLBALDH1A1L3MBTL1GAA
SCHEMBL8330397 0.81 LMNA (0.51) LMNAPOLBALDH1A1L3MBTL1GAA
SCHEMBL316573 0.81 LMNA (0.51) LMNAPOLBALDH1A1L3MBTL1GAA
SCHEMBL30353214 0.80 LMNA (0.50) LMNAPOLBALDH1A1L3MBTL1GAA
SCHEMBL11816701 0.78 LMNA (0.49) LMNAPOLBALDH1A1L3MBTL1GAA
SCHEMBL411131 0.78 CSNK2A2 (0.32)
SCHEMBL26931875 0.72 LMNA (0.47) LMNAPOLBALDH1A1L3MBTL1GAA
SCHEMBL11816692 0.70 ALDH1A1 (0.43) LMNAPOLBALDH1A1L3MBTL1GAA
SCHEMBL11809971 0.70 ALDH1A1 (0.50) LMNAPOLBALDH1A1L3MBTL1GAA
SCHEMBL6389347 0.70 LMNA (0.46) LMNAPOLBALDH1A1L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8716314-B2 Isotopologues of thalidomide CELGENE CORPORATION (US) 2014-05-06 US disclosed
US-20120064004-A1 ISOTOPOLOGUES OF THALIDOMIDE CELGENE CORPORATION 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064004-A1 ISOTOPOLOGUES OF THALIDOMIDE CDK4, FKBP8, FKBP1A LMNA 4457/4885POLB 1400/4885ALDH1A1 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.